Back to News
Market Impact: 0.2
NeoGenomics Receives Medicare Coverage for RaDaR ST for Immunotherapy Treatment Response Monitoring
Source: businesswire.com
Company FundamentalsTechnology & InnovationHealthcare & BiotechProduct Launches
NeoGenomics said it has expanded MolDX coverage for its RaDaR ST MRD assay, used for immunotherapy monitoring in late-stage solid tumors. The update is incremental and supportive for commercialization, but no financial figures or guidance changes were provided.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.15
Ticker Sentiment
NEO0.30
More News
- Nvidia GPUs are everywhere. Here are the ways companies are accessing them
- Bank of America is bullish on these top stocks ahead of earnings
- As companies pour billions into Earth-based AI infrastructure, Google is taking the data center race off-planet
- How U.S. know-how is fracking Australia into a gas boom, from Texas oilmen to Trump’s energy secretary
- The world needs Ukraine’s grain. Its farmers are running out of reasons to plant
- Verizon stock heads for worst day since 2002 as SpaceX U.S. network plans whack telcos